Characteristics of study population (n = 285).

<p>Characteristics of study population (n = 285).</p

Unadjusted and multivariable associations between self-reported TSE, measurable saliva cotinine, and airborne apartment nicotine.

<p>Unadjusted and multivariable associations between self-reported TSE, measurable saliva cotinine, and airborne apartment nicotine.</p

Distribution of saliva cotinine and apartment nicotine levels by self-reported TSE.

<p>Distribution of saliva cotinine and apartment nicotine levels by self-reported TSE.</p

Agreement between self-reported TSE and measurable cotinine and airborne nicotine.

<p>Agreement between self-reported TSE and measurable cotinine and airborne nicotine.</p

Rates of drug-seeking diagnosis and associated actions for the sciatica “patient”.

<p>Rates of drug-seeking diagnosis and associated actions for the sciatica “patient”.</p

Judgments about drug seeking by medication requested among physicians who mentioned drug seeking in the qualitative interview for sciatica patient (N = 52).

<p>Judgments about drug seeking by medication requested among physicians who mentioned drug seeking in the qualitative interview for sciatica patient (N = 52).</p

Patient (simulated) and physician characteristics, N = 192.

<p>Patient (simulated) and physician characteristics, N = 192.</p

Final multivariable model predicting a diagnosis of drug-seeking for the sciatica “patient”.

<p>Final multivariable model predicting a diagnosis of drug-seeking for the sciatica “patient”.</p

Quotations supporting drug-seeking judgment rationales.

<p>Quotations supporting drug-seeking judgment rationales.</p

Top 20 univariate markers across all outcome measures.

<p>Each numeric entry indicates the number of statistical tests in which the described analyte was found to be a statistically significant biomarker when evaluated for regression against the given outcome measures or categorical characteristics: SMA Types, Disease Onset, Current Level of Function and Respiratory Support. Each outcome measure or characteristic inherently has a certain number of possible sub-categories available for pairwise statistical testing (in parentheses for each outcome or characteristic): 12 for SMA Types, 5 for Disease Onset, 15 for current level of function and 4 for Respiratory Support (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0035462#pone.0035462.s001" target="_blank">Table S1</a> for details). The Total denotes the sum of all outcomes for which the protein is a marker and indicates the overall strength of the relationship between the analyte and SMA values; the maximum possible number for Total is 36, as all the analytes above are also statistical significant regressors with the MHMS outcome. AAA – Amino acid analysis; FFA – Free fatty acid; Q-VALUE – significance corrected for the effect of multiple comparisons; STD – Standard deviation; UCL – Upper 95% confidence limit; LCL – lower 95% confidence limit (on the value of slope). Slope values listed in red are positive values and those in green negative values.*These are distinct isoforms detected by the LC/MS method.</p